If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 32
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
Objective
IIT-GEORGE-I-PREDICT
Protocol No
IIT-GEORGE-I-PREDICT
Categories
Cancer,
Colorectal,
Gynecologic Cancers,
Esophagus,
Other Urologic,
Head and Neck Cancers,
Early Phase/Multiple Disease Site Cancers,
Esophagus,
Skin Cancers,
Stomach,
Prostate and Urologic Cancers,
Pancreas/Liver,
Breast Cancers,
Other Gastrointestinal,
Sarcoma,
Gastrointestinal Cancers,
Lung,
Thoracic Cancers
A Phase 1/2, Open-Label, Multicenter, First-in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors
Objective
The purpose of this study is to learn more about an investigational drug called DS-3939a. DS-3939a is an investigational drug that is not approved for your disease. It is being studied to see if it is safe and if your disease or medical condition improves while taking it.
Protocol No
DAIICHI-SANKYO-DS3939-077
Categories
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
Objective
PLDR CRT for esophageal cancer
Protocol No
IIT-PUCKETT-PULSO
Categories
An Open-Label, Phase 1, Multi-Center Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive fo
Objective
A Phase1 Study of NT-112 in Patients with Advanced Solid Tumors Positive for KRAS G12D Mutation
Protocol No
NEOGENE-NT-112-301
REMASTer: REcurrent Brain Metastases After SRS Trial
Objective
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Protocol No
MONTERIS-CL10153-REMASTER
Categories
Cancer,
Endocrine Cancers,
Uterine,
Other Urologic,
Colorectal,
Cervix,
Lung,
Brain and Spine Cancers,
Prostate,
Stomach,
Skin Cancers,
Prostate and Urologic Cancers,
Other Respiratory,
Gastrointestinal Cancers,
Breast Cancers,
Head and Neck Cancers,
Esophagus,
Ovary,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Gynecologic Cancers,
Sarcoma,
Eye/Orbital Cancers
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Objective
A First-in-Human, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Protocol No
XILIO-XTX301-01-02-001
A Phase 1b/2, Multicenter, Open-Label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-Line Induction or Maintenance, in Subjects with Extensive-Stage
Objective
A Phase 1b 2 Study of I-DXd, ADC, in Combination in Patients with ES-SCLC
Protocol No
DAIICHI-SANKYO-DS7300-189
Categories
A First-in-Human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients with Locally Advanced Un-Resectable and/or Metastatic Solid Tumors and Multiple Myeloma
Objective
Safety, PK and efficacy of QXL138AM in patients with solid tumors and multiple myeloma
Protocol No
NAMMI-QXL138AM-001
PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer
Objective
A Phase II randomized study evaluating Durvalumab with or without personalized treatment for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Protocol No
SWOG-S2409-PRISM
Categories
A Phase 1, Open-Label, Multicenter, First-in-Human Trial of DS3610A in Participants With Advanced Solid Tumors
Objective
A Phase 1 Study of DS3610A in participants with advance solid tumor cancer.
Protocol No
DAIICHI-DS3610-071
Categories
Cancer,
Early Phase/Multiple Disease Site Cancers,
Lip, Oral Cavity and Pharynx,
Other Skin,
Other Respiratory,
Colorectal,
Pancreas/Liver,
Skin Cancers,
Other Gynecologic,
Other Gastrointestinal,
Ovary,
Prostate,
Thoracic Cancers,
Gastrointestinal Cancers,
Sarcoma,
Uterine,
Kidney,
Gynecologic Cancers,
Breast Cancers,
Eye/Orbital Cancers,
Head and Neck Cancers,
Other Urologic,
Endocrine Cancers,
Prostate and Urologic Cancers